Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Kansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 42 | 2,193 | 20% |
| 2020 | 46 | 2,034 | 23% |
| 2021 | 46 | 2,177 | 28% |
| 2022 | 43 | 2,139 | 31% |
| 2023 | 43 | 2,291 | 34% |
| 2024 | 44 | 2,107 | 36% |
| 2025 from claims | – | 2,364 2,169–2,501 | 36% |
| 2026 forecast | – | 2,422 2,131–2,795 | 36% |
| 2027 forecast | – | 2,480 2,120–2,956 | 36% |
| 2028 forecast | – | 2,540 2,120–3,110 | 37% |
| 2029 forecast | – | 2,601 2,125–3,262 | 37% |
| 2030 forecast | – | 2,664 2,134–3,414 | 37% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 41% of the cases CMS names in Kansas; 27 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 8% inpatient hospital, 72% hospital outpatient, 20% surgery center. The share outside the hospital has moved +11 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 150 | 6,970−0.5%/yr | −0.5%/yr | 6.4 | 12% | 7,740 in 2030+1.8%/yr |
| Illinois | 148 | 6,158−2.8%/yr | −2.8%/yr | 4.5 | 13% | 6,630 in 2030+1.2%/yr |
| Indiana | 105 | 5,228−0.5%/yr | −0.5%/yr | 7.5 | 11% | 6,130 in 2030+2.7%/yr |
| Michigan | 94 | 4,688−5.4%/yr | −5.4%/yr | 5.6 | 6% | 4,480 in 2030−0.8%/yr |
| Missouri | 83 | 3,766−2.6%/yr | −2.6%/yr | 6.1 | 19% | 4,330 in 2030+2.4%/yr |
| Wisconsin | 63 | 2,490−3.4%/yr | −3.4%/yr | 4.5 | 6% | 2,900 in 2030+2.6%/yr |
| Minnesota | 47 | 1,837−5.2%/yr | −5.2%/yr | 4.1 | 5% | 2,500 in 2030+5.3%/yr |
| Iowa | 47 | 1,750−0.8%/yr | −0.8%/yr | 4.0 | 26% | 1,840 in 2030+0.9%/yr |
| Nebraska | 35 | 1,512−0.1%/yr | −0.1%/yr | 5.8 | 12% | 1,880 in 2030+3.7%/yr |
| South Dakota | 18 | 618+1.8%/yr | +1.8%/yr | 4.8 | 0% | 810 in 2030+4.6%/yr |
| North Dakota | 10 | 352−6.2%/yr | −6.2%/yr | 3.6 | 0% | 360 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 37 | 2,068−4.1%/yr | −4.1%/yr | 5.11.1× | 37% | 1,920 in 2030−1.3%/yr |
| Incontinence, prolapse & sacral neuromodulation | 15 | 1,028−2.4%/yr | −2.4%/yr | 2.51.1× | 21% | 990 in 2030−0.6%/yr |
| Hysterectomy, hysteroscopy & ablation | 14 | 868−1.5%/yr | −1.5%/yr | 2.30.8× | 11% | 890 in 2030+0.4%/yr |
| Prostatectomy & nephrectomy | 10 | 583−1.8%/yr | −1.8%/yr | 1.51.1× | 0% | 720 in 2030+3.6%/yr |
Kidney stone management in every state, and its device makers · Every procedure market in Kansas · Every state · Compare with Ohio
Boston Scientific leads with 36% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 4 companies reported engagement with Kansas’s surgeons worth $48K in consulting, speaking, meals and travel tied to these products, about $1,089 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.